RANDOMIZED STUDY OF PHASE III, WITH PACLITAXEL VERSUS PACLITAXEL MAS BEVACIZUMAB (RHU MBA VEGF) AS A FIRST-LINE TREATMENT FOR METASTASIC OR LOCALLY RECURRING BREAST CANCER

Authors
Category Primary study
Registry of TrialsClinical Trials Peruvian Registry
Year 2004
This article has no abstract
Epistemonikos ID: 36cbe8456055b15307a934e9898a5e8aa021d162
First added on: Apr 16, 2025